Modeling human neurological disorders with induced pluripotent stem cells
Authors:
- 15 December 2013
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 129 (3) , 388-399
Abstract
Human induced pluripotent stem (iPS) cells obtained by reprogramming technology are a source of great hope, not only in terms of applications in regenerative medicine, such as cell transplantation therapy, but also for modeling human diseases and new drug development. In particular, the production of iPS cells from the somatic cells of patients with intractable diseases and their subsequent differentiation into cells at affected sites (e.g., neurons, cardiomyocytes, hepatocytes, and myocytes) has permitted the in vitro construction of disease models that contain patient‐specific genetic information. For example, disease‐specific iPS cells have been established from patients with neuropsychiatric disorders, including schizophrenia and autism, as well as from those with neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. A multi‐omics analysis of neural cells originating from patient‐derived iPS cells may thus enable investigators to elucidate the pathogenic mechanisms of neurological diseases that have heretofore been unknown. In addition, large‐scale screening of chemical libraries with disease‐specific iPS cells is currently underway and is expected to lead to new drug discovery. Accordingly, this review outlines the progress made via the use of patient‐derived iPS cells toward the modeling of neurological disorders, the testing of existing drugs, and the discovery of new drugs. image The production of human induced pluripotent stem (iPS) cells from the patients' somatic cells and their subsequent differentiation into specific cells have permitted the in vitro construction of disease models that contain patient‐specific genetic information. Furthermore, innovations of gene‐editing technologies on iPS cells are enabling new approaches for illuminating the pathogenic mechanisms of human diseases. In this review article, we outlined the current status of neurological diseases‐specific iPS cell research and described recently obtained knowledge in the form of actual examples.Keywords
Funding Information
- Japan Science and Technology Agency
This publication has 82 references indexed in Scilit:
- Sustained Mobilization of Endogenous Neural Progenitors Delays Disease Progression in a Transgenic Model of Huntington’s DiseaseCell Stem Cell, 2013
- A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin SusceptibilityCell, 2013
- Induced pluripotent stem cells: the new patient?Nature Reviews Molecular Cell Biology, 2012
- Genetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem CellsCell Stem Cell, 2012
- Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndromeHuman Molecular Genetics, 2012
- The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activityNeurobiology of Disease, 2012
- Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerabilityProceedings of the National Academy of Sciences, 2012
- Isogenic Pairs of Wild Type and Mutant Induced Pluripotent Stem Cell (iPSC) Lines from Rett Syndrome Patients as In Vitro Disease ModelPLOS ONE, 2011
- Direct generation of functional dopaminergic neurons from mouse and human fibroblastsNature, 2011
- Modelling schizophrenia using human induced pluripotent stem cellsNature, 2011